Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.36 |
| ▸ | THRB | P10828 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
| ▸ | PPARG | P37231 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14194987 | 1.00 | MAPT (0.36) | MAPTTHRBLMNATP53GRM2 | |
| SCHEMBL1855249 | 0.97 | MAPT (0.35) | MAPTTHRBLMNATP53GRM2 | |
| SCHEMBL1864970 | 0.94 | MAPT (0.36) | MAPTTHRBLMNATP53GRM2 | |
| SCHEMBL1859041 | 0.91 | PTPRF (0.36) | MAPTTHRBLMNATP53GRM2 | |
| SCHEMBL4825154 | 0.91 | PTPRF (0.36) | MAPTTHRBLMNATP53GRM2 | |
| SCHEMBL4820701 | 0.90 | PTPRF (0.35) | MAPTTHRBLMNATP53GRM2 | |
| SCHEMBL1863184 | 0.90 | MAPT (0.38) | MAPTTHRBLMNATP53PPARG | |
| SCHEMBL14194982 | 0.90 | MAPT (0.38) | MAPTTHRBLMNATP53PPARG | |
| SCHEMBL4820708 | 0.89 | GRM2 (0.33) | MAPTTHRBLMNATP53GRM2 | |
| SCHEMBL4819031 | 0.88 | PPARA (0.40) | PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7365064-B2 | Benzoxazine and benzothiazine derivatives and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES LIMITED (IN) | 2008-04-29 | — | — | US | claimed |
| US-20050113368-A1 | Benzoxazine and benzothiazine derivatives and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES LIMITED (IN) | 2005-05-26 | — | — | US | claimed |
| EP-1436268-A1 | BENZOXAZINE AND BENZOTHIAZINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Dr. Reddy's Laboratories Ltd. (IN) | 2004-07-14 | — | — | EP | claimed |
| WO-2003033481-A1 | BENZOXAZINE AND BENZOTHIAZINE DERIVATIVES AND PARMACEUTICAL COMPOSITIONS CONTAINING THEM | DR. REDDY'S LABORATORIES LTD. (IN) | 2003-04-24 | — | — | WO | claimed |
| US-20110105748-A1 | Novel beta-phenyl-alpha-oxysubstituted propionic derivatives: process for its preparation and their use in the preparation of pharmaceutically important compounds | REDDY'S LABORATORIES INC. | 2011-05-05 | — | — | US | disclosed |
| US-7365064-B2 | Benzoxazine and benzothiazine derivatives and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES LIMITED (IN) | 2008-04-29 | — | — | US | disclosed |
| US-20050113368-A1 | Benzoxazine and benzothiazine derivatives and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES LIMITED (IN) | 2005-05-26 | — | — | US | disclosed |
| EP-1436247-A1 | NOVEL-BETA-PHENYL-ALPHA-OXYSUBSTITUTED PROPIONIC DERIVATIVES: PROCESS FOR ITS PREPARATION AND THEIR USE IN THE PREPARATION OF PHARMACEUTICALLY IMPORTANT COMPOUNDS | Dr. Reddy's Laboratories Ltd. (IN) | 2004-07-14 | — | — | EP | disclosed |
| EP-1436268-A1 | BENZOXAZINE AND BENZOTHIAZINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Dr. Reddy's Laboratories Ltd. (IN) | 2004-07-14 | — | — | EP | disclosed |
| WO-2003033481-A1 | BENZOXAZINE AND BENZOTHIAZINE DERIVATIVES AND PARMACEUTICAL COMPOSITIONS CONTAINING THEM | DR. REDDY'S LABORATORIES LTD. (IN) | 2003-04-24 | — | — | WO | disclosed |
| WO-2003033456-A1 | NOVEL β-PHENYL-α-OXYSUBSTITUTED PROPIONIC DERIVATIVES: PROCESS FOR ITS PREPARATION AND THEIR USE IN THE PREPARATION OF PHARMACEUTICALLY IMPORTANT COMPOUNDS | DR. REDDY'S LABORATORIES LTD. (IN) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105748-A1 | Novel beta-phenyl-alpha-oxysubstituted propionic derivatives: process for its preparation and their use in the preparation of pharmaceutically important compounds | PCCA, ADRA1B, ADRA2B | MAPT 1308/4885THRB 879/4885LMNA 2490/4885 |
| US-20050113368-A1 | Benzoxazine and benzothiazine derivatives and pharmaceutical compositions containing them | CYP3A5, HBZ, CYP4Z1 | MAPT 566/4885THRB 462/4885LMNA 1046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.